Novel 2-Benzoyl-6-(2,3-Dimethoxybenzylidene)-Cyclohexenol Confers Selectivity toward Human MLH1 Defective Cancer...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• DNA mismatch repair (MMR) deficiency is linked to increased risk and chemoresistance in colorectal, endometrial, and ovarian cancers.
• Limited effective treatment options exist for patients with MMR-deficient cancers, highlighting the need for novel therapeutic strategies.
• Targeting specific molecular defects, like MLH1 deficiency, is a promising avenue for selective cancer therapy.

Purpose of the Study:

• To identify novel drug leads with synthetic lethal activity against MLH1-deficient cancer cells.
• To screen a library of natural compounds for selective toxicity in MMR-deficient cancer models.
• To explore the mechanism of action of identified compounds.

Main Methods:

• Screening of commercial and semisynthetic natural compounds using MLH1 isogenic colorectal cancer cell lines and various cancer cell lines with known MLH1 status.
• Identification and characterization of a novel diarylpentanoid analogue, AS13.
• Assessment of AS13's selective toxicity and mechanism of action, including induction of oxidative stress and DNA damage.

Main Results:

• AS13, a novel diarylpentanoid analogue, demonstrated selective toxicity towards MLH1-deficient cancer cells.
• AS13 was found to induce elevated levels of oxidative stress, leading to DNA damage.
• Only MLH1-proficient cells could repair the induced DNA damage, allowing them to survive, while MLH1-deficient cells underwent cell death.

Conclusions:

• AS13 is a promising lead compound for developing new drugs targeting MLH1-deficient cancers.
• The compound's mechanism involves inducing oxidative stress and DNA damage, selectively impacting MMR-deficient cells.
• Further drug development based on AS13 could lead to improved treatment options for patients with MLH1-deficient malignancies.